17 May 2018 07:00
Horizon Discovery Group plc
Board Change
Cambridge, UK, 17 May 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that Dr. Jonathan Milner is stepping down from his position as a Non-Executive Director of the Board with immediate effect.
Commenting on this announcement, Dr. Jonathan Milner said: "After 10 very enjoyable years on the Horizon Board I have decided to step down, to free more time to concentrate on my other interests. I have immensely liked working with the Horizon team, and would like to take this opportunity to thank my fellow Board members for such an enjoyable experience. From my initial meeting with the founders through to the IPO, and becoming a world leader in gene editing, I feel enormously privileged to have been a part of this exciting journey. I continue to be encouraged and enthusiastic about the growth prospects of Horizon's business, and intend to remain a shareholder for the foreseeable future."
Dr. Ian Gilham, Executive Chairman of the Board of Directors, Horizon Discovery, said: "We are sorry to see Jonathan depart, but completely understand his decision to prioritise other commitments. We are extremely grateful for his valuable insights as a member of Horizon's Board over many years and wish him well in his future, not least as a considerable founding shareholder of the Horizon business."
As of 15th May 2018, Dr. Jonathan Milner owned a total of 10,815,172 ordinary shares of Horizon Discovery Group plc (7.25% of the Company's issued share capital), and 20,888,110 ordinary shares of Abcam plc (10.21% of the Company's issued share capital).
Horizon's Board consists of the following representatives:
Dr Ian Gilham
Executive Chairman
Terry Pizzie
Chief Executive Officer
Richard Vellacott
Chief Financial Officer
Mrs Susan Searle
Non-Executive Director
Dr Susan Galbraith
Non-Executive Director
Dr Vishal Gulati
Non-Executive Director
Mr Grahame Cook
Non-Executive Director
ENDS
For further information from Horizon Discovery Group plc, please contact:
Horizon Discovery Group plc
Ian Gilham, Executive Chairman
Terry Pizzie, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.
Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".